All In Biotech

Drug Trial Radar · NCT01720446

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)

Last checked: Nov 19, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,297 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,297

Actual

Start

Feb 21, 2013

Primary completion

Mar 15, 2016

Study completion Mar 15, 2016

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • semaglutideDrug

    Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)

  • semaglutideDrug

    Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)

  • placeboDrug

    Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal StrokeTime frame: Time from randomisation up to end of follow-up (scheduled at week 109)

Locations

253 sites in 21 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Chandler, Arizona

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Greenbrae, California

  • Novo Nordisk Investigational Site

    Lancaster, California

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Mission Hills, California

  • Novo Nordisk Investigational Site

    Monterey, California

  • Novo Nordisk Investigational Site

    Northridge, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Ramon, California

  • Novo Nordisk Investigational Site

    Ventura, California

  • Novo Nordisk Investigational Site

    Aurora, Colorado

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Bradenton, Florida

  • Novo Nordisk Investigational Site

    Crystal River, Florida

  • Novo Nordisk Investigational Site

    DeLand, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Melbourne, Florida

  • Novo Nordisk Investigational Site

    Melbourne, Florida

  • Novo Nordisk Investigational Site

    Ocala, Florida

  • Novo Nordisk Investigational Site

    Ponte Vedra, Florida

  • Novo Nordisk Investigational Site

    Spring Hill, Florida

  • Novo Nordisk Investigational Site

    St. Petersburg, Florida

  • Novo Nordisk Investigational Site

    Dunwoody, Georgia

  • Novo Nordisk Investigational Site

    Lawrenceville, Georgia

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Crystal Lake, Illinois

  • Novo Nordisk Investigational Site

    Gurnee, Illinois

  • Novo Nordisk Investigational Site

    Michigan City, Indiana

  • Novo Nordisk Investigational Site

    Mishawaka, Indiana

  • Novo Nordisk Investigational Site

    Wichita, Kansas

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Monroe, Louisiana

  • Novo Nordisk Investigational Site

    New Orleans, Louisiana

  • Novo Nordisk Investigational Site

    Methuen, Massachusetts

  • Novo Nordisk Investigational Site

    North Dartmouth, Massachusetts

  • Novo Nordisk Investigational Site

    Kalamazoo, Michigan

Showing 40 of 253 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.